ArticleAmerican journal of translational research2025
Endovascular therapy for iliac vein compression syndrome: superior outcomes in non-thrombotic patients and risk factors for stent restenosis.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the long-term efficacy and thrombotic outcomes of endovascular therapy for iliac vein compression syndrome (IVCS), with a focus on identifying risk factors for postoperative stent restenosis.
methodsThis retrospective cohort study analyzed 98 IVCS patients treated with endovascular therapy at Hefei First People's Hospital between January 2020 and December 2022. Patients were divided into non-thrombotic (NIVCS, n=48) and acute thrombotic (TIVCS, n=50) groups. Outcomes included 1-year stent patency, complications, and quality-of-life metrics (CIVIQ-20 and VCSS scores). Logistic regression was used to identify risk factors for restenosis, with diagnostic performance accessed via ROC analysis.
resultsThe NIVCS group demonstrated significantly better 1-year stent patency (91.67% vs. 74%, P=0.018) but higher complication rates (20% vs. 8.33%, P=0.025) compared to the TIVCS group. Both groups showed significant improvements in CIVIQ-20 and VCSS scores (P<0.05), with NIVCS patients achieving better final outcomes. Multivariate analysis identified thrombotic IVCS (OR=3.41, 95% CI: 1.28-9.07), body mass index ≥28 kg/m
conclusionEndovascular therapy effectively improves symptoms and quality of life in IVCS, particularly in non-thrombotic cases. The thrombotic subtype, obesity, and hypertension significantly influence long-term stent patency, highlighting the need for personalized postoperative management. These findings underscore the potential of risk-stratified therapeutic strategies in vascular interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.